Related Experiment Videos
Ticarcillin-induced neutropenia corroborated by in vitro CFU-C toxicity
Abstract:
A patient developed a drug rash and neutropenia while receiving tobramycin, ticarcillin and flucloxacillin intravenously for osteomyelitis. Incorporation of these antibiotics into in vitro cultures of bone marrow granulocyte macrophage precursors (CFU-C) showed no inhibition of the patient's marrow or normal marrow by tobramycin. The patient's marrow was more sensitive to ticarcillin than were control cultures, and all cultures incorporating flucloxacillin failed to show growth of CFU-C. Drugs of the penicillin group appear to be responsible for the patient's neutropenia.
Insights
A patient experienced neutropenia during antibiotic treatment for osteomyelitis. Flucloxacillin, a penicillin-class antibiotic, was identified as the likely cause, inhibiting bone marrow precursor growth in vitro.
Area of Science:
- Pharmacology
- Hematology
- Infectious Diseases
Background:
- Osteomyelitis treatment often involves intravenous antibiotics.
- Drug-induced neutropenia is a potential adverse effect of antibiotic therapy.
Observation:
- A patient developed a drug rash and neutropenia while undergoing intravenous treatment with tobramycin, ticarcillin, and flucloxacillin for osteomyelitis.
- In vitro studies were conducted using bone marrow granulocyte macrophage precursors (CFU-C).
Findings:
- Tobramycin did not inhibit the patient's or normal bone marrow CFU-C.
- The patient's bone marrow exhibited increased sensitivity to ticarcillin compared to control cultures.
- Flucloxacillin completely inhibited CFU-C growth in all cultures.
Implications:
- Penicillin-class antibiotics, specifically flucloxacillin, are implicated as the cause of the patient's neutropenia.
- This case highlights the importance of monitoring for neutropenia during treatment with certain antibiotic combinations.
- In vitro CFU-C assays can be valuable in investigating drug-induced hematologic toxicities.